Over the last 5 years, 68Ga-labeled prostate-specific membrane antigen (68Ga-PSMA) PET/CT has gained widespread use to assess PCa (33, 34), which could identify metastatic lesions in lymph node, bone, and soft tissue at low PSA levels (33–35). The gene discussed is FOLH1; the disease is posterior cortical atrophy.